Knockout/Knockdown Validation
 

GeneTex understands the absolute necessity for reliable antibodies to achieve accurate and reproducible experimental results. To optimize the performance of our reagents, we employ various analytic validation strategies to ensure both consistent quality (see GeneTex's Approach to Antibody Lot-to-Lot Variability) and specificity. These modalities are in line with guidelines described by the International Working Group on Antibody Validation (IWGAV) and have become fundamental components of our quality assurance process:

 

 

    Knockout/ Knockdown Knockout/ Knockdown
Complete or significant reduction of signal following genome editing or RNA interference of target protein.
 
    Comparative antibodies Comparable antibodies
Correlation between two antibodies against the same target with different epitopes across several samples, preferentially with different expression levels of the target protein.
 
    IP-MS IP-MS
Mass spec analysis of target protein peptide sequences from samples immunoprecipitated by antibody from lysates.
 
    Biological and orthogonal characteristics Biological and orthogonal characteristics
Change of antibody signal in accordance with defined biological characteristics of target protein following specific sample preparation parameters, including drug treatments, hypoxia conditions, or subcellular fractionation. Also, analysis of signals from various cell lines that either do or do not express the target in the context of protein or mRNA levels.
 
    Protein Overexpression Protein Overexpression
To confirm the endogenous signals detected by the antibody are the target protein, transfected cells with cDNA encoding the target protein are used as a positive control and independently validated by western blot.
 

 

 

Product datasheets display the corresponding certification icon(s) to identify those antibodies that have satisfied one or more of these validation methods.

 

  Knockout/ Knockdown Knockout/ Knockdown  
 

NFkB p65 antibody(GTX102090)


NFkB p65 antibody
(GTX102090
KOKD

 

Cyclin D1 antibody [N1C3] (GTX108624)


Cyclin D1 antibody [N1C3]
(GTX108624
KOKD

 

Galectin 3 antibody(GTX125897)


Galectin 3 antibody
(GTX125897
KOKD

 

Integrin beta 1 / CD29 antibody(GTX128839)


Integrin beta 1 / CD29 antibody
(GTX128839
KOKD

 

 

  Comparative antibodies Comparable antibodies  
 

PD-L1 antibody(GTX104763)


PD-L1 antibody
(GTX104763

 

Her2 / ErbB2 antibody (GTX100509)


Her2 / ErbB2 antibody
(GTX100509

 

alpha Synuclein antibody(GTX133367)


alpha Synuclein antibody
(GTX133367

 

14-3-3 antibody(GTX133736)


14-3-3 antibody
(GTX133736

 

 

  Biological and orthogonal characteristics  
 

LC3B antibody (GTX127375)


LC3B antibody
(GTX127375

 

p21 Cip1 antibody (GTX100444)


p21 Cip1 antibody
(GTX100444

 

HIF1 alpha antibody (GTX127309)


HIF1 alpha antibody
(GTX127309

 

Glypican 1 antibody [N3C3] (GTX104557)


Glypican 1 antibody [N3C3]
(GTX104557

 

 

  Protein Overexpression Protein Overexpression  
 

NFkB p65 antibody(GTX107678)


NFkB p65 antibody
(GTX107678

 

MYH10 antibody [GT246] (GTX634160)


MYH10 antibody [GT246]
(GTX634160

 

Aurora A antibody(GTX134461)


Aurora A antibody
(GTX134461

 

JNK1/2 antibody (GTX133806)


JNK1/2 antibody
(GTX133806

 

 

 

 

References:
1. Nat Methods. 2016 Oct;13(10):823-7.